Cargando…

New options for the medical treatment of Cushing's syndrome

A number of drugs have been advocated for the medical management of Cushing's syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination. Cabergoline may be of value in a minority of patients but pasir...

Descripción completa

Detalles Bibliográficos
Autor principal: Trainer, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683198/
https://www.ncbi.nlm.nih.gov/pubmed/23776896
http://dx.doi.org/10.4103/2230-8210.109685
_version_ 1782273469479649280
author Trainer, Peter J.
author_facet Trainer, Peter J.
author_sort Trainer, Peter J.
collection PubMed
description A number of drugs have been advocated for the medical management of Cushing's syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination. Cabergoline may be of value in a minority of patients but pasireotide is a more reliable and effective agent that lowers cortisol secretion in the great majority of patients, although only normalises UFC in a minority. The potential for combination of an agent that blocks adrenal steroidogenesis with inhibition of ACTH secretion by pasireotide needs to be explored.
format Online
Article
Text
id pubmed-3683198
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36831982013-06-17 New options for the medical treatment of Cushing's syndrome Trainer, Peter J. Indian J Endocrinol Metab ESICON 2012 Kolkata Mini-Review A number of drugs have been advocated for the medical management of Cushing's syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination. Cabergoline may be of value in a minority of patients but pasireotide is a more reliable and effective agent that lowers cortisol secretion in the great majority of patients, although only normalises UFC in a minority. The potential for combination of an agent that blocks adrenal steroidogenesis with inhibition of ACTH secretion by pasireotide needs to be explored. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3683198/ /pubmed/23776896 http://dx.doi.org/10.4103/2230-8210.109685 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle ESICON 2012 Kolkata Mini-Review
Trainer, Peter J.
New options for the medical treatment of Cushing's syndrome
title New options for the medical treatment of Cushing's syndrome
title_full New options for the medical treatment of Cushing's syndrome
title_fullStr New options for the medical treatment of Cushing's syndrome
title_full_unstemmed New options for the medical treatment of Cushing's syndrome
title_short New options for the medical treatment of Cushing's syndrome
title_sort new options for the medical treatment of cushing's syndrome
topic ESICON 2012 Kolkata Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683198/
https://www.ncbi.nlm.nih.gov/pubmed/23776896
http://dx.doi.org/10.4103/2230-8210.109685
work_keys_str_mv AT trainerpeterj newoptionsforthemedicaltreatmentofcushingssyndrome